Aidoc has raised US$150m to expand CARE, its clinical AI platform that helps doctors make faster, more accurate medical decisions at the point of care.
The funding round was led by General Catalyst and Square Peg, with support from NVentures (NVIDIA’s venture capital arm) and four major US health systems: Hartford HealthCare, Mercy, Sutter Health and WellSpan Health.
The round includes a US$40m revolving credit facility, bringing the company’s total funding to US$370m.
The company says clinical AI can help tackle the 371,000 annual deaths caused by diagnostic errors by identifying high-risk findings, automating follow-ups and speeding up care.
Elad Walach, chief executive officer of Aidoc, said: “Our mission is to reduce diagnostic errors and improve patient outcomes.
“CARE compresses decades of roadmap into years, bringing forward a future where AI supports every patient encounter, helping physicians provide the care they believe their patients deserve.”
The funding will also support expansion of aiOS, Aidoc’s enterprise-grade platform for deploying and governing clinical AI at scale.
It enables hospitals to run multiple AI tools with real-time performance monitoring, seamless integration and measurable outcomes.
CARE, a foundation model trained on multimodal data such as medical images and clinical notes, is designed to develop new clinical tools up to 20 times faster than traditional methods.
With unmatched clinical accuracy, all Aidoc models will transition to CARE.
Within three years, it is expected to support diagnosis and treatment for 90 per cent of clinically relevant diseases, including cancer and cardiovascular conditions.
Michael Braginsky, co-founder and chief technology officer of Aidoc, said: “Model accuracy is paramount when touching the core of a physician’s work.
“Foundation models will soon be as ubiquitous in healthcare as ChatGPT is in general use.
“Scaling clinical AI is an enormous lift – it requires top-tier talent, powerful infrastructure, deep real-world insight and sustained funding.
“Success isn’t guaranteed, but we believe we’re in a unique position to bring this vision to life, and we feel a deep responsibility to do so.”
